- Home
- MESO vs JBLU Comparison
MESO vs JBLU Comparison
Compare MESO & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- JBLU
- Stock Information
- Founded
- MESO 2004
- JBLU 1998
- Country
- MESO Australia
- JBLU United States
- Employees
- MESO N/A
- JBLU N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- JBLU Air Freight/Delivery Services
- Sector
- MESO Health Care
- JBLU Consumer Discretionary
- Exchange
- MESO Nasdaq
- JBLU Nasdaq
- Market Cap
- MESO 1.3B
- JBLU 1.5B
- IPO Year
- MESO N/A
- JBLU N/A
- Fundamental
- Price
- MESO $15.17
- JBLU $4.27
- Analyst Decision
- MESO Buy
- JBLU Sell
- Analyst Count
- MESO 4
- JBLU 11
- Target Price
- MESO $18.00
- JBLU $4.97
- AVG Volume (30 Days)
- MESO 314.4K
- JBLU 19.5M
- Earning Date
- MESO 08-28-2025
- JBLU 07-29-2025
- Dividend Yield
- MESO N/A
- JBLU N/A
- EPS Growth
- MESO N/A
- JBLU N/A
- EPS
- MESO N/A
- JBLU N/A
- Revenue
- MESO $5,670,000.00
- JBLU $9,138,000,000.00
- Revenue This Year
- MESO $177.23
- JBLU N/A
- Revenue Next Year
- MESO $314.04
- JBLU $7.77
- P/E Ratio
- MESO N/A
- JBLU N/A
- Revenue Growth
- MESO N/A
- JBLU N/A
- 52 Week Low
- MESO $5.78
- JBLU $3.34
- 52 Week High
- MESO $22.00
- JBLU $8.31
- Technical
- Relative Strength Index (RSI)
- MESO 60.94
- JBLU 44.49
- Support Level
- MESO $14.45
- JBLU $4.30
- Resistance Level
- MESO $16.23
- JBLU $5.07
- Average True Range (ATR)
- MESO 0.57
- JBLU 0.21
- MACD
- MESO 0.10
- JBLU 0.00
- Stochastic Oscillator
- MESO 63.12
- JBLU 12.09
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.